Contraindicated (1)bortezomib will enhance the level or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or average CYP2C19 inhibitors may increase mavacamten systemic publicity, resulting in coronary heart failure because of systolic dysfunction. The sq. root of two could be the frequency ratio of a tritone interval https://danteicume.glifeblog.com/26390610/the-single-best-strategy-to-use-for-lp-pla2-in-1